Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fruquintinib × HMPL-013 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 29 Stomach Neoplasms 9 Colonic Neoplasms 3 Rectal Neoplasms 2 Carcinoma, Hepatocellular 2 Advanced Colorectal Carcinoma 2 Sarcoma 1 Patients With Advanced Metastatic Colorectal Cancer 1 Pancreatic Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 NSCLC 1 Metastatic Colorectal Adenocarcinoma 1 Metastasis Colorectal Cancer 1 Lung Neoplasms 1 Locally Advanced Rectal Cancer 1 Gastric/Gastroesophageal Junction Adenocarcinoma 1 Gastric Cancer Adenocarcinoma Metastatic 1 Fruquintinib 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Cancer Metastatic 1 Biliary Tract Adenocarcinoma 1 Advanced Solid Tumors 1 Advanced Gastric Cancer 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡